The BH3-only pro-apoptotic proteins are upstream sensors of cellular damage that selectively respond to specific, proximal death and survival signals. Genetic models and biochemical studies indicate that these molecules are latent killers until activated through transcriptional or post-translational mechanisms in a tissue-restricted and signal-specific manner. The large number of BH3-only proteins, their unique subcellular localization, protein-interaction network and diverse modes of activation suggest specialization of their damage-sensing function, ensuring that the core apoptotic machinery is poised to receive input from a wide range of cellular stress signals. The apoptotic response initiated by the activation of BH3-only proteins ultimately culminates in allosteric activation of pro-apoptotic BAX and BAK, the gateway proteins to the mitochondrial pathway of apoptosis. From activation of BH3-only proteins to oligomerization of BAX and BAK and mitochondrial outer membrane permeabilization, an intricate network of interactions between the pro-and anti-apoptotic members of the BCL-2 family orchestrates the decision to undergo apoptosis. Beyond regulation of apoptosis, multiple BCL-2 proteins have recently emerged as active components of select homeostatic pathways carrying other cellular functions. This review focuses on BAD, which was the first BH3-only protein linked to proximal survival signals through phosphorylation by survival kinases. In addition to findings that delineated the physiological role of BAD in apoptosis and its dynamic regulation by phosphorylation, studies pointing to new roles for this protein in other physiological pathways, such as glucose metabolism, are highlighted. By executing its 'day' and 'night' jobs in metabolism and apoptosis, respectively, BAD helps coordinate mitochondrial fuel metabolism and the apoptotic machinery.
Introduction
The BCL-2 family of cell death regulators constitutes a critical control point in the intrinsic pathway of apoptosis governing mitochondrial outer membrane permeabilization and the subsequent release of apoptogenic factors (Danial and Korsmeyer, 2004; Chipuk and Green, 2008; Youle and Strasser, 2008) . Selective protein interactions among different pro-and antiapoptotic members of this family are central to their regulation of apoptosis. These interactions are chiefly influenced by a-helical segments known as BCL-2 homology (BH) domains and comprise both cytosolic and membrane conformers of select family members (Leber et al., 2007) . Pro-apoptotic BAX and BAK and all anti-apoptotic members of the family, such as BCL-2 and BCL-X L , are 'multidomain' family members that share sequence homology within three to four BH domains ( Figure 1 ). The BH3-only pro-apoptotic proteins, such as BAD, BID, BIM, NOXA and PUMA, share homology within a single amphipathic BH segment, the BH3 domain, which is also known as the minimum death domain. BAX and BAK constitute a gateway to mitochondrial apoptosis in that their combined deletion affords resistance to all death stimuli that activate the intrinsic pathway of apoptosis (Lindsten et al., 2000; Wei et al., 2001) . BH3-only proteins are cell death initiators, the pro-apoptotic activity of which is latent unless activated. Post-translational modifications, such as phosphorylation, proteolytic processing and lipid modification of BH3-only proteins, have emerged as possible mechanisms that dynamically integrate extracellular survival and death signals with the core apoptotic machinery at the mitochondrion (Danial and Korsmeyer, 2004; Youle and Strasser, 2008) . The pro-apoptotic activity of BH3-only proteins is further triggered by the exposure of the hydrophobic face of their BH3 domain, facilitating interaction with a hydrophobic groove present in multidomain partner proteins. This interaction can ultimately lead to BAX and BAK activation through both direct and indirect mechanisms. Structural studies and mutational analysis suggest that neutralization of anti-apoptotic molecules and direct activation of BAX and BAK are both necessary for the induction of mitochondrial outer membrane permeabilization by apoptotic stimuli (Leber et al., 2007; Chipuk and Green, 2008) . Although some BH3-only proteins can interact with both anti-and pro-apoptotic molecules, others such as BAD only bind and neutralize anti-apoptotic BCL-2 partners (Letai et al., 2002; Chen et al., 2005; Kuwana et al., 2005; Kim et al., 2006; Walensky et al., 2006; Billen et al., 2008; Gavathiotis et al., 2008) .
Although in vitro studies showed that overexpression of BH3-only molecules in a variety of cell lines leads to apoptosis, genetic loss-of-function models indicate that individual BH3-only proteins serve as cell death initiators responding to selected signals in restricted cell types. The lack of a universal defect in apoptosis on deletion of a single BH3-only molecule may be explained in part by the functional redundancies among these proapoptotic proteins, the degree of which may vary depending on the specific cell type or death signal examined. The multiplicity of BH3-only proteins and restricted apoptosis defects associated with their ablation could also denote specialization, enabling the core apoptotic machinery to receive extensive input under different stress conditions, such as DNA damage, metabolic decline, growth factor withdrawal, hypoxic insult and unfolded proteins.
It has become increasingly clear that BCL-2 family proteins may have cellular functions beyond regulation of apoptosis. Several BCL-2 proteins regulate the Ca 2 þ stores at the endoplasmic reticulum and affect Ca 2 þ homeostasis (Pinton and Rizzuto, 2006) . In addition, these proteins may influence other homeostatic pathways, such as autophagy . The BH3-only protein BAD regulates glucose-driven mitochondrial respiration, insulin secretion and glucose homeostasis in vivo . BID, on the other hand, is a downstream substrate for DNAdamage checkpoint kinases ATM/ATR and plays a role in intra-S-phase checkpoint (Kamer et al., 2005; Zinkel et al., 2005) . In healthy cells, BAX and BAK influence the dynamics of mitochondrial tubules by controlling mitochondrial fusion and fission, processes known to dynamically control the mitochondrial network affecting the efficiency of fuel oxidation, ATP synthesis and Ca 2 þ buffering (Karbowski et al., 2006) . The above findings are but four examples of an emerging notion that BCL-2 family members are integral components of distinct cellular homeostatic pathways that carry 'day jobs' separate from their capacity to regulate apoptosis (Danial and Korsmeyer, 2004; Cheng et al., 2006) . By being embedded in these processes, they serve as critical checkpoints for death when cellular homeostasis is violated. A link between trophic factor signaling and the core apoptotic machinery Post-translational regulation of BAD's pro-apoptotic function Although signals transduced by the engagement of growth factor receptors, such as cytokines, insulin-likegrowth factor (IGF) and nerve growth factor (NGF), were long known to promote survival, the molecular mechanisms linking their survival-promoting effect to the direct inhibition of apoptosis emerged with the identification of select components of the core apoptotic machinery that are modulated by phosphorylation events downstream of survival signaling Amaravadi and Thompson, 2005 ). BAD's capacity to bind and neutralize its anti-apoptotic partners, BCL-2, BCL-X L and BCL-W, is inhibited on phosphorylation by survival kinases activated by trophic factors (Figure 2a ). Mapping of BAD phosphorylation sites has revealed three evolutionarily conserved serine residues (S112, S136 and S155, mouse BAD L enumeration) (Zha et al., 1996; Datta et al., 2000; Lizcano et al., 2000; Tan et al., 2000; Virdee et al., 2000; Zhou et al., 2000a) . Among these, S155 lies within the BAD BH3 domain, which binds the hydrophobic groove of anti-apoptotic partners (Ottilie et al., 1997; Zha et al., 1997; Kelekar and Thompson, 1998; Petros et al., 2000) (Figure 2 ). The negative charge of phosphorylated serine at this position renders the interaction between the BAD BH3 helix and the hydrophobic groove of anti-apoptotic BCL-2 energetically unfavorable.
Combinatorial mutation of the three serine residues has provided evidence for a tiered or sequential phosphorylation model in which S155 modification itself requires priming phosphorylation on S136 and S112 residues (Datta et al., 2000) . S136 phosphorylation appears to be an apical event that is independent of the phosphorylation status of S112 or S155. On phosphorylation, both S112 and S136 bind 14-3-3 proteins ( Figure 2a) ; however, pS136 may be the more predominant 14-3-3-binding site Chiang et al., 2003) . Docking of 14-3-3 on phosphorylated S136 may in turn induce conformational changes that allow access of S155 kinases to the BAD BH3 domain. This interpretation is in agreement with mutational studies showing that the substitution of S136 with alanine interferes with S155 phosphorylation (Datta et al., 2000) . However, evidence for a ternary complex containing BAD phosphorylated on S136, BCL-2/X L and 14-3-3 proteins, which would be predicted as an intermediate step in this sequential phosphorylation model, has not been put forward (Zha et al., 1996; Datta et al., 2000) . It is also possible that such a ternary complex may be transient in nature. Structural studies will likely provide important insights into the mechanisms by which modification of residues upstream of the BAD BH3 domain regulates the interaction interface of the BH3 domain and its ligands. Furthermore, the requirement of 14-3-3 proteins in mediating S155 phosphorylation awaits the analysis of interaction-defective or loss-of-function 14-3-3 mutants. The tiered phosphorylation model of BAD inactivation proposes that modification of at least two serine residues is required to fully neutralize its apoptotic activity. Consistent with this notion, preventing either S136 or S155 phosphorylation impairs the growth-factormediated protection of cerebellar granule neurons from apoptosis (Datta et al., 2000) . Furthermore, the S155D or S155E mutants that mimic a constitutively phosphorylated BAD afforded protection from apoptosis regardless of the S112 and S136 phosphorylation status, suggesting that S155 phosphorylation is the final, perhaps rate-limiting modification, required for neutralizing the apoptotic function of BAD (Datta et al., 2000; Tan et al., 2000) .
BAD phosphorylation may not only alter its association with anti-apoptotic proteins, but it may further influence its subcellular localization. Initial studies have suggested that the phosphorylation-dependent association of BAD with 14-3-3 proteins shifts its localization from mitochondria to the cytosol (Zha et al., 1996) . Once dephosphorylated on growth factor withdrawal, BAD translocates to the mitochondria and associates with anti-apoptotic BCL-2 family partners. However, regulatory mechanisms in charge of BAD subcellular localization appear to be more complex. For example, in healthy cells, a portion of phosphorylated BAD can reside at mitochondria . Recent findings have provided important insights into BCL-X L BAD P P P BCL-X L BAD BH3 S155 BAD P P P S155 S136 S112
14-3-3 14-3-3 BAD Figure 2 Regulation of BAD's apoptotic activity by phosphorylation. (a) Phosphorylation of three serine sites regulates the interaction of BAD and its anti-apoptotic partners such as BCL-X L . Phosphorylation of S112 and S136 allows 14-3-3 docking. (Jeong et al., 2004; Billen et al., 2008) . In healthy cells, the C-terminal tail anchor of BCL-X L is not available for membrane insertion because of homodimerization (Jeong et al., 2004) . On association with BAD, the C-terminal domain of BCL-X L is displaced and available for insertion into the mitochondrial membrane. Lipid-binding properties of BAD may further facilitate this process, as evidenced by the finding that a BAD mutant compromised in lipid binding but capable of interacting with BCL-X L in solution proved deficient in promoting the mitochondrial translocation of BCL-X L (Hekman et al., 2006) . Interestingly, the affinity of BAD for negatively charged lipids at the mitochondrial membrane is diminished on association with the 14-3-3 protein. These findings uncover additional regulatory mechanisms that modulate the proapoptotic activity of BAD and warrant investigation to define the precise connection between BAD lipidbinding dynamics and the accessibility of kinases/ phosphatases to the three serine sites. In addition to phosphorylation, the pro-apoptotic activity of BAD is modulated by caspase cleavage on cytokine withdrawal, death receptor engagement and transforming-growth factor-b treatment (Condorelli et al., 2001; Kim et al., 2002; Seo et al., 2004) . In vitro studies have indicated that BAD can be cleaved by caspase-2, -3, -7, -8, -10 and granzyme B (Condorelli et al., 2001) . The N-terminally truncated BAD is poorly phosphorylated and less likely to interact with 14-3-3, but appears to have a higher affinity for BCL-X L and the mitochondrial membrane. These properties are consistent with the observation that caspase-cleaved BAD is a more potent inducer of cytochrome c release and apoptosis (Condorelli et al., 2001; Seo et al., 2004) . Whether BAD cleavage occurs selectively at the mitochondrial membrane is not fully clear. The ability of truncated BAD to enhance FAS-induced apoptosis is analogous to the effects of another BH3-only protein BID, which on caspase cleavage initiates a mitochondrial amplification loop during apoptosis induced by death receptors (Li et al., 1998; Luo et al., 1998) . Characterization of the molecular interplay between the two types of post-translational modifications that impinge on BAD, phosphorylation and proteolytic cleavage may uncover additional regulatory mechanisms underlying BAD's function.
BAD kinases
Depending on the cellular context, various kinases have been shown to phosphorylate BAD (Figure 3 ). S136 is a preferred substrate for AKT and p70S6 kinases in the PI3K signaling pathway (Datta et al., 1997; del Peso et al., 1997; Blume-Jensen et al., 1998; Eves et al., 1998; Harada et al., 2001) . S112 and S155 harbor bona fide protein kinase A (PKA) consensus sites that can also be recognized by p90 ribosomal S6 kinase (p90RSK), a kinase activated by the MAPK pathway that shares multiple common substrates with PKA (Datta et al., 2000; Tan et al., 2000; Houslay, 2006) . Modification of BAD by p90RSK is consistent with several studies indicating that the activation of the RAS/RAF/MEK/ MAPK pathway modulates BAD phosphorylation Fang et al., 1999; Scheid et al., 1999) . RAF can localize to mitochondria (Wang et al., 1996a; Gotz et al., 2005) , and its activated forms promote BAD phosphorylation (Fang et al., 1999) . However, RAF modulation of BAD phosphorylation is likely indirect through other kinases such as AKT (Fang et al., 1999; Wiese et al., 2001; von Gise et al., 2001; Gotz et al., 2005) . PIM kinases constitute another class of survival kinases that phosphorylate BAD predominantly on the S112 site (Fox et al., 2003; Yan et al., 2003; Macdonald et al., 2006) . Unlike many of the above survival kinases, PIM activation is chiefly controlled at the transcriptional levels through Signal Transducers and Activators of Transcription (STAT) proteins downstream of cytokine receptors (Fox et al., 2003) (Figure 3 ). S112 phosphorylation is also modulated by p21-activated kinases (PAKs), which propagate survival signaling downstream of G-protein-coupled receptors, cytokine receptors and the Rho GTPases, such as CDC42 and RAC1 (Schurmann et al., 2000; Gnesutta et al., 2001; Cotteret et al., 2003; Sastry et al., 2006 Sastry et al., , 2007 (Figure 3 ). Within the PAK family of kinases, PAK4 and PAK5 associate with the mitochondrion (Cotteret et al., 2003) . Although the majority of BAD phosphorylation events inactivate its pro-apoptotic function, one study has suggested that BAD phosphorylation on Ser 128 by cdc2 negatively affects 14-3-3 binding and enhances the pro-apoptotic function of BAD in cerebellar granule neurons (Konishi et al., 2002) . The interrelationship of these phosphorylation events is especially intriguing as it suggests that BAD modification may serve as a node where distinct signaling pathways converge to regulate the core apoptotic machinery.
Survival and death signals modulate BAD phosphorylation by tipping the balance of kinases and phosphatases. Similar to BAD kinases, BAD phosphatases are context-and cell-type-specific. Several BAD phosphatases have been characterized within specific death paradigms, including calcineurin (Wang et al., 1999) , PP2A (Chiang et al., , 2003 and PP1 (Ayllon et al., 2000; Salomoni et al., 2000; Danial et al., 2003; Djouder et al., 2007) . These phosphatases may preferentially target selective serine sites in BAD. The efficiency of phosphatases in charge of pS112 and pS136 dephosphorylation directly correlates with their ability to displace 14-3-3 proteins ). As pS155 is not a 14-3-3-binding site, the rate-limiting step in its dephosphorylation is likely more complex. It is also possible that the dissociation of 14-3-3 from pS112 and pS136 is sufficient to allow phosphatase access to pS155 (Chiang et al., 2003) . Recent studies have proposed a sequential model of BAD dephosphorylation initiated by pS112 dephosphorylation, which may then expose pS136 and pS155 residues for dephosphorylation (Chiang et al., 2003) . Thus, both phosphorylation and dephosphorylation of BAD at the three serine sites seem to be tiered processes. Although S136 is the apical serine the phosphorylation of which is needed for neutralizing BAD's apoptotic function, pS112 dephosphorylation may be the initial dephosphorylation event required for promoting the apoptotic activity of BAD. It is also possible that, in addition to directly targeting specific serine sites, BAD phosphatases may inactivate the survival kinases (Andjelkovic et al., 1996; Djouder et al., 2007) . Mitochondria-tethered signaling complexes relay survival signals to BAD phosphorylation Among the kinases in charge of BAD phosphorylation, PKA and p70S6K were biochemically purified as mitochondrial-tethered activities that phosphorylate BAD (Harada et al., 1999 (Harada et al., , 2001 . This is especially relevant as BCL-2 family interactions are highly focused at the mitochondrial membrane, where family members regulate the release of apoptogenic factors (Leber et al., 2007) . As many of the kinases in charge of BAD modification are ubiquitously expressed, mechanisms that tether signaling complexes to mitochondria are requisite to specifically direct their activity toward BAD (Figure 4 ). For example, mitochondrial targeting of PKA is ensured by scaffold proteins known as A Kinase Anchoring Proteins (AKAPs) that spatially constrain the PKA holoenzyme complex to specific subcellular sites for selective response to localized cAMP gradients and for robust phosphorylation of preferred substrates (Taylor et al., 2004; Beene and Scott, 2007) . AKAPs bind the regulatory subunit of the PKA holoenzyme complex that normally holds the catalytic subunits inactive. Binding of cAMP to regulatory subunits leads to the release of catalytic subunits. AKAPs may also bind PKA substrates, ensuring their proximity to the holoenzyme complex. To date, D-AKAP1 (AKAP121) and WAVE-1 are two AKAPs implicated in BAD phosphorylation by tethering PKA to mitochondria in interleukin (IL)-3-dependent hematopoietic cells and hepatocytes, respectively (Harada et al., 1999; Danial et al., 2003) . In agreement with the pro-survival role of mitochondria-anchored PKA, interference with PKA anchoring or mutations in D-AKAP1 that compromise its ability to bind PKA or localize to mitochondria impair BAD phosphorylation and sensitize cells to apoptosis even in the presence of survival factors (Harada et al., 1999; Affaitati et al., 2003) . Furthermore, these AKAP-containing signaling complexes contain the serine/threonine phosphatase PP1, ensuring that BAD phosphorylation is the net outcome of kinase/phosphatase activities (Figure 4 ). Whether the phosphatase within these mitochondrial signaling complexes directly dephosphorylates BAD or indirectly attenuates the kinase awaits further studies. Recently, a distinct PP1-containing complex was implicated in the attenuation of another BAD survival kinase, p70S6K (Djouder et al., 2007) . PP1g was shown to reside in a mitochondrial signaling complex together with Unconventional prefoldin RPB5 Interactor (URI), a member of the prefoldin family of chaperones that normally keeps PP1g in a dormant state (Figure 4 ). Phosphorylation of URI by p70S6K leads to the release and activation of PP1g in a negative feedback loop that inactivates p70S6K and inhibits BAD phosphorylation on S136 (Djouder et al., 2007) . Knockdown of URI interferes with the propagation of p70S6K signaling to BAD and promotes cell death that is dependent on PP1g activation of BAD's apoptotic function. These findings, however, do not exclude the possibility that concomitant with the inhibition of p70S6K, PP1g dephosphorylates and activates BAD directly. Other mitochondrial-tethered signaling complexes in charge of BAD S136 phosphorylation have also been reported. A multiprotein complex containing the heat-shock protein-70 co-chaperon BAG1, RAF and AKT helps focus these kinase activities toward BAD at mitochondria (Gotz et al., 2005) (Figure 4 ). S136 phosphorylation in this complex is likely directly mediated by AKT, which may in turn be activated by RAF. In the absence of BAG1, RAF and AKT fail to associate with mitochondria, and phosphorylation of BAD on S136 is impaired. Within this signaling complex, BAG1 serves both as a scaffold targeting RAF and AKT to mitochondria and as an activator of RAF1 kinase (Wang et al., 1996b; Gotz et al., 2005) . The BAG1-dependent activation of survival kinases in this context explains, at least in part, the severe survival defects of neuronal and hematopoietic progenitors derived from BAG1-deficient mice (Gotz et al., 2005) . The distinct mitochondria-resident complexes in charge of BAD phosphorylation suggest that an intricate signaling circuitry controlled by trophic factors is in place to antagonize apoptotic signals and to protect cells from mitochondrial dysfunction. In addition to genetic approaches that allow the examination of complex assembly in the absence of select complex components, biochemical studies are required to examine the mode of complex assembly and to specifically dissect whether the complexes are pre-assembled at the mitochondria or are dynamically assembled/disassembled in the presence or absence of growth factors. This is especially relevant as BAD phosphorylation/ dephosphorylation within these complexes may be accompanied by extensive conformational changes in complex constituents leading to the retention or release of select components. In line with this thesis, a stoichiometric relationship of the complex components would be highly instructive.
In addition to controlling the phosphorylation status of BAD, the above signaling complexes may modulate other aspects of mitochondrial functions that may in turn be integrated with cellular life and death decisions. As such, identifying additional mitochondrial substrates and functions for these signaling complexes will provide important clues. Indeed, D-AKAP1 and WAVE-1 affect several other mitochondrial parameters, including respiration (Livigni et al., 2006) and mitochondrial dynamics (Sung et al., 2008) . Although D-AKAP1 appears to be exclusively anchored to the mitochondrial outer membrane (Chen et al., 1997; Huang et al., 1997) , the mechanism underlying its ability to activate components of the mitochondrial respiratory chains in the inner mitochondrial membrane is not fully clear. It is possible that the tethering of PKA to mitochondrial outer membrane may help the efficiency of mitochondrial respiration by stimulating the import of nuclear encoded subunits of the respiratory chains (De Rasmo et al., 2008) . Unlike D-AKAP1, the mitochondrial localization of WAVE-1 is not restricted to mitochondrial outer membrane and may prove integral to its role in the morphogenesis of dendritic spines and neuronal connectivity (Soderling et al., 2007) . This may be further attuned to the WAVE-1-dependent regulation of mitochondrial fission and distribution along dendritic spines (Sung et al., 2008) . Through its effect on actin polymerization, WAVE-1 may regulate mitochondrial trafficking by promoting the short distant movement of this organelle, a cellular process known to be actin dependent (Ligon and Steward, 2000; Westphal et al., 2000) . Efficient transport of mitochondria along dendritic spines may be further facilitated by mitochondrial fission (Li et al., 2004b) . Although the above AKAP-based mitochondrial signaling complexes may be separate from those reported for BAD, the common regulatory mechanisms that converge to modulate both mitochondrial apoptotic machinery and mitochondrial respiration and dynamics are but another indication of the intricate coordination between BCL-2 family proteins and mitochondrial physiology.
BAD: a sentinel for select apoptotic signals
Although in vitro studies showed BAD phosphorylation as a mechanism by which trophic factors inhibit mitochondrial apoptosis, knock-in mice bearing a nonphosphorylatable mutant of BAD in which S112, S136 and S155 were mutated to alanine (Bad 3SA ) provided a stringent test for the physiological significance of BAD dephosphorylation in apoptosis (Datta et al., 2002) . Bad 3SA mice show selective defects in B-and T-cell development marked by impairment of IL-7-dependent survival of pro-B and pro-T cells and a significant diminution of thymic and bone marrow cellularity. BAD phosphorylation appears to be a significant component of IL-7-dependent T-cell survival (Datta et al., 2002; Li et al., 2004a) . Consistent with these findings, transgenic mice overexpressing BAD in the Tcell compartment showed abnormalities in T-cell development and apoptosis, including a significant reduction in thymic cellularity and T-cell maturation (Mok et al., 1999) . Bad transgenic thymocytes are significantly more sensitive to apoptosis induced by g irradiation, dexamethasone and anti-Fas antibody in a manner that can be partially rescued by a Bcl-2 transgene (Mok et al., 1999) . Although these gain-of-function models point to the physiological role of BAD in T-cell development and apoptosis, loss of BAD's pro-apoptotic function as in Bad-null mice is not associated with any defects in thymocyte survival and development . This may be indicative of functional redundancies among BH3-only proteins during T-cell development.
Characterization of the BAD-deficient and phosphorylation knock-in mouse models showed that inhibition of BAD's pro-apoptotic activity phenocopies trophic factor antagonism of apoptotic stimuli. For example, in the absence of serum BadÀ/À primary mouse embryonic fibroblasts exposed to etoposide or an antiFas antibody, or BadÀ/À mammary epithelial cells subjected to epidermal growth factor withdrawal are significantly protected from apoptosis . Likewise, the examination of cerebellar granule neurons derived from Bad 3SA knock-in mice indicated that BAD phosphorylation mechanistically underlies the ability of IGF-I to counteract apoptotic stimuli (Datta et al., 2002) . However, Bad 3SA neurons were residually protected from apoptosis in the presence of IGF-I, suggesting that trophic factors can partially support neuronal survival in the absence of BAD. The residual survival of Bad 3SA neuronal cultures in this setting is likely due to the inactivation of FKHRL1 by survival signaling (Datta et al., 2002) . FKHRL1 is a Forkhead family transcription factor capable of transactivating pro-apoptotic genes, such as Fas ligand, Trail, Noxa and Bim Gilley et al., 2003; Obexer et al., 2007) . Phosphorylation by AKT normally blocks nuclear translocation of FKHRL1 . In addition to FKHRL-1 inactivation, phosphorylation and stabilization of X-linked inhibitor of apoptosis protein by AKT may further account for the residual IGF-I-mediated protection of Bad 3SA neurons (Dan et al., 2004) . Taken together, these findings suggest that BAD phosphorylation is a major, but not the sole, mechanism by which trophic factors inactivate the apoptotic machinery.
Beyond the growth factor withdrawal paradigms of apoptosis, BAD is an important sentinel in death induced by hypoxic injury in vivo (Ness et al., 2006) . Death caused by hypoxic insult has both apoptotic and necrotic components. Analogous to glutamate toxicity, hypoxic injury is associated with massive metabolic decline and impairment of ion homeostasis marked by calcium overload and mitochondrial dysfunction (Orrenius et al., 2003) . During hypoxic injury, BAD's pro-apoptotic function may be activated on inhibition of survival kinases or activation of phosphatases such as calcineurin (Wang et al., 1999) . In agreement with this notion, sustained PI3K/AKT signaling and BAD phosphorylation are associated with neuroprotection afforded by ischemic preconditioning, which is a short period of ischemic insult that shields neurons from subsequent ischemia (Noshita et al., 2001; Yano et al., 2001; Gidday, 2006; Miyawaki et al., 2008) . Remarkably, the protective effect of ischemic preconditioning in this experimental paradigm occurs despite caspase-3 activation (Miyawaki et al., 2008) . Emerging studies suggest that, beyond apoptosis, regulated interaction of BAD and BAD-like ligands and BCL-X L in neurons may further influence cellular bioenergetics and determine the ATP levels available for synapse formation or recovery after ischemic insult (Hickman et al., 2008) . Specifically, the interaction of BAD and BCL-X L may affect the refilling of synaptic vesicles and trafficking of mitochondria to synaptic termini for efficient neurotransmission (Jonas et al., 2003; Li et al., 2008) . The precise molecular mechanisms underlying the regulation of synaptic transmission by these BCL-2 family members are just beginning to be unraveled.
BAD and tumor cell apoptosis
Loss-of-function models of several BH3-only proteins are associated with increased incidence of tumors (Labi et al., 2006) . Over time, Bad-deficient mice show an increased death rate from tumors. Histological analysis indicated that the most prominent malignancy in BADdeficient mice is diffuse large B-cell lymphoma of the germinal center or post-germinal center B220 þ CD19 þ B cells expressing the zinc finger transcription factor BCL-6 . Solid tumors have also been noted in these mice. The latency of tumor development suggests accumulation of secondary mutations or abnormalities beyond ablation of Bad. Consistent with this idea, irradiation of BAD-deficient mice accelerated tumorigenicity . Interestingly, the majority of tumors after irradiation were pro/pre-B-and T-cell lymphoblastic leukemia/lymphoma. This is particularly intriguing as the inactivation of BAD's proapoptotic function by phosphorylation appears to play a prominent role in the survival of these lymphocyte populations (Datta et al., 2002; Li et al., 2004a) . In light of these findings, tumor studies in Bad 3SA mice may be warranted. Given the exaggerated sensitivity of B and T cells to apoptosis in this genetic model, Bad 3SA mice are predicted to be resistant to tumor development. Unlike these experimental models, an examination of genetic alterations of Bad in human malignancies has not provided evidence for somatic mutations in human lymphoma. However, loss of BAD's pro-apoptotic function has been reported in a variety of solid tumors in humans. For example, analysis of the Bad coding region in colon adenocarcinomas indicated somatic mutations in 4.3% of the samples that reduced the apoptotic activity of BAD and mapped to its BH3 domain (E113K and L114F, corresponding to E150 and L151 in the murine BAD sequence) . Other studies have reported a significant increase in phosphorylated BAD in B60% of colorectal carcinomas, which showed positive correlation with high levels of phosphorylated AKT in some cases (Khor et al., 2004; Kim et al., 2007) .
The functional requirement of BAD in sensitizing tumors to apoptosis has been the subject of several recent studies. The survival and proliferation of solid tumors such as glioblastoma, prostrate and breast cancer are often associated with gain of function in epidermal growth factor receptor signaling and loss-offunction in PTEN, leading to constitutive activation of the Ras/MAPK and PI3K/AKT pathways, respectively (Li et al., 1997; Samuels et al., 2004) . Enhanced survival in this setting is associated with an elevated BAD phosphorylation on S112 and S136, which, when inhibited, sensitizes cells to apoptosis (She et al., 2005) . These data provide a possible molecular mechanism underlying the synergy between the antitumor effects of RAS/MAPK and PI3K/AKT inhibitors (Lee et al., 2003; Uzgare and Isaacs, 2004) . Other studies have shown that the pro-apoptotic effect of select chemotherapeutic drugs is mediated through BAD. For example, apoptosis induced by imatinib, an inhibitor of the BcrAbl oncogene in chronic myelogenous and acute lymphoblastic leukemia, requires the combined apoptotic activities of BAD and BIM (Kuroda et al., 2006) . Consistent with this conclusion, imatinib treatment is associated with decreased BAD phosphorylation and elevated levels of BIM. BAD is also necessary for the pro-apoptotic effects of a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, ZD1839 (Iressa), in both normal and malignant breast epithelium (Gilmore et al., 2002) . BAD is dephosphorylated in response to ZD1839, and primary mammary epithelial cultures derived from BAD-deficient mice proved resistant to the toxic effect of this drug. Likewise, loss-of-function studies in a mouse model of prostate cancer underscored a physiologically relevant role for BAD in tumor regression induced by omega-3 and omega-6 polyunsaturated fatty acids (Berquin et al., 2007) . While BAD phosphorylation is a component of the survival program driven by the oncogenic activation of select kinases, BAD dephosphorylation may contribute to the pro-apoptotic effects of certain tumor suppressors. Consistent with this possibility, inhibition of BAD phosphorylation by p70S6K downstream of the tumor suppressor tuberin (TSC2), has been proposed as a major mechanism by which TSC-2 induces apoptosis (Freilinger et al., 2006) (Figure 3) . Remarkably, the sensitizing effects of BAD in tumor cell apoptosis can be mimicked by small molecules that bind the hydrophobic groove of BCL-2, BCL-X L and BCL-W analogous to the BAD BH3 domain. ABT737 is a BAD BH3 mimetic compound with promising antitumor activity in lymphoma, leukemia and small cell lung carcinoma (Oltersdorf et al., 2005; Deng et al., 2007) .
Beyond apoptosis
BAD and cell cycle progression Several anti-and pro-apoptotic members of the BCL-2 family are known to affect cell cycle progression (Zinkel et al., 2006) . BAD counters G0/G1 arrest induced by serum withdrawal or overexpression of anti-apoptotic BCL-2 and BCL-X L, and aberrantly drives cells through the S phase (Chattopadhyay et al., 2001; Janumyan et al., 2003) . The cell cycle effects of BAD are reported both in fibroblasts and thymocytes (Mok et al., 1999; Chattopadhyay et al., 2001) . The percentage of thymocytes in S phase increased B3-fold in a Bad transgenic model compared with non-transgenic counterparts. BAD's effect on cell cycle depends on its BH3 domain, requires its ability to engage BCL-2/BCL-X L and is associated with persistent CDK2 activity (Chattopadhyay et al., 2001) . The cell cycle effect of BAD appears to be separate from its role in apoptosis in a manner that is not fully understood at the molecular level. Among potential scenarios, a role for alterations in mitochondrial bioenergetics downstream of BAD/BCL-X L heterodimers has been suggested. This possibility is in line with recent studies showing that cellular energy balance, specifically the efficiency of mitochondrial electron transport, affects cell cycle progression by regulating cyclin E-CDK2 activity (Mandal et al., 2005; OwusuAnsah et al., 2008) . Particularly, genetic dissection of the cross talk between mitochondria and cell cycle machinery in Drosophila has revealed that two indicators of mitochondrial electron transport efficiency, ATP and ROS levels, control the activation status of AMPactivated protein kinase (AMPK) and JNK, respectively (Owusu-Ansah et al., 2008) . AMPK and JNK activation are linked to inhibition of cyclin E-CDK2 activity. AMPK is a cellular energy sensor activated by rising AMP levels, which mirrors the drop in the ATP/ADP ratio. Through its downstream substrates, AMPK stimulates catabolic pathways and inactivates ATPconsuming anabolic pathways such as protein synthesis and cell cycle progression (Hardie, 2007) . Two AMPK substrates, p53 and cyclin E-CDK2 inhibitor p27, help propagate its effect on cell cycle. AMPK phosphorylation of p53 leads to its cell cycle inhibitory function, including downregulation of cyclin E levels (Imamura et al., 2001; Jones et al., 2005) . AMPK phosphorylation also increases the protein stability of p27 (Liang et al., 2007) . In the context of suboptimal mitochondrial function, p27 levels are further increased in response to moderate elevation of ROS and subsequent JNK activation (Owusu-Ansah et al., 2008) . Thus, G1/S transition appears to be tightly coordinated with cellular energy balance. In light of these findings, it is possible that BAD's effect in driving cells through the S phase, even in the presence of G1/S blockers, may stem from its modulation of mitochondrial energy metabolism.
BAD and autophagy
Regulation of cellular metabolic status, including energy balance (ATP/ADP ratio) and redox potential (NADH/ NAD þ ratio), is an essential component of survival factor signaling (DeBerardinis et al., 2008) . Accumulating evidence suggests that growth factors target expression, modification and activities of key metabolic enzymes and alter cellular metabolic flux and mitochondrial function that ultimately affect apoptosis, cell cycle progression, cell growth and aging (Marshall, 2006; Robey and Hay, 2006; Giorgio et al., 2007; DeBerardinis et al., 2008) . Consequently, growth factor withdrawal is associated with metabolic decline, including a drop in cellular ATP levels, blunted glycolytic rates, decrease in O 2 consumption, inhibition of protein synthesis and induction of apoptosis (Gottlob et al., 2001; Vander Heiden et al., 2001) . In response to such metabolic stress and nutrient starvation, the cells activate autophagy to maintain energy balance. Autophagy is primarily a housekeeping mechanism that serves to degrade long-lived proteins and damaged organelles. This process is regulated by an evolutionarily conserved set of proteins that ultimately orchestrate the recruitment of protein/organelle cargo to vesicles that will deliver their contents to lysosomes (Reggiori and Klionsky, 2002) . Under metabolic stress, the breakdown of organelles and proteins in autophagosomes produces amino acids and metabolites that can then feed into the mitochondrial tricarboxylic acid cycle, sustaining the production of FADH 2 and NADH, which ensures that the flow of electrons through the mitochondrial respiratory chain complexes remains uninterrupted. The bioenergetic benefits of autophagy are temporary until the metabolic stress is eliminated (for example, growth factor or oxygen availability). In addition to survival in the face of nutrient starvation or other environmental stress, autophagy plays a role in tissue remodeling and genomic stability (Karantza-Wadsworth et al., 2007; .
The survival signaling pathway and autophagy are integrated to preserve the cellular bioenergetic balance. Survival signaling inhibits autophagy through the mammalian target of rapamycin (mTOR) kinase, which serves as a nutrient sensor that is activated by high levels of ATP, glucose or amino acids, and in turn stimulates protein synthesis (Blommaart et al., 1995) . During nutrient starvation, AMPK inactivates mTOR and releases the 'brake' on autophagy (Figure 3) . The fact that autophagy and survival signaling are highly intertwined homeostatic pathways was underscored by the discovery that BCL-2 interacts with and inhibits Beclin 1 (Atg 6), an evolutionarily conserved protein that promotes autophagosome formation (Liang et al., 1998; Pattingre et al., 2005) . This interaction is directly mediated through a BH3 domain present in Beclin 1 (Maiuri et al., 2007; Oberstein et al., 2007) . Whether autophagy is primarily a form of cell death or a means of cellular survival is the subject of intense investigation (Lockshin and Zakeri, 2004; Levine and Yuan, 2005) . Current findings support the notion that autophagy is primarily a self-limiting survival pathway and a temporary adaptive response during metabolic stress used by the cell before its fate is determined: survival if the metabolic stress is resolved or death if cellular stress persists and autophagy continues beyond physiological levels. Inactivation of autophagy during metabolic decline and nutrient stress leads to apoptosis, unless apoptosis is inactivated (for example, BAX/BAK deficiency), in which case cell death occurs through necrosis (Lum et al., 2005) .
Through competition with Beclin 1, BH3-only proteins, including BAD and BAD mimetic compound ABT737, can displace Beclin 1 and block the inhibitory effect of BCL-2/BCL-X L on autophagy (Maiuri et al., 2007) . Importantly, the autophagy-promoting effect of BAD and ABT737 is restricted to their select neutralization of endoplasmic reticulum-resident pool of BCL-2/ BCL-X L, separate from modulation of apoptosis. Lossand gain-of-function studies confirmed a physiological role for BAD in autophagy (Maiuri et al., 2007) . As the availability of the BAD BH3 domain for binding to BCL-2/BCL-X L is heavily influenced by phosphorylation downstream of the growth factors and nutrientsensing pathways, BAD may integrate nutrient availability with an adaptive autophagic response. Interestingly, overexpression of BAD promoted steady-state levels of autophagy in the absence of nutrient starvation (Maiuri et al., 2007) . This may be an indication that in healthy cells, in the absence of nutrient decline, BAD may participate in quality control mechanisms that rely on autophagy to rid the cells of damaged organelles, especially dysfunctional mitochondria (Twig et al., 2008) .
BAD and glucose metabolism
The link between BAD and glucose metabolism was first discovered through proteomic analysis of liver mitochondria, which revealed that BAD resides in a multiprotein complex together with PKA and PP1, WiskottAldrich family member WAVE-1, serving as an AKAP and glucokinase (GK, hexokinase IV), the product of Mody-2 gene (Maturity Onset Diabetes of the Young type 2) . GK is the high Km isoform of mammalian hexokinases whose expression is restricted to islet b-cells, hepatocytes and glucose-sensing neurons in the hypothalamus (Matschinsky et al., 2006) . As a key component of the mammalian glucose-sensing machinery, GK plays important roles in glucosestimulated insulin secretion in pancreatic b-cells, glucose storage and production in hepatocytes and neuroendocrine regulation of food intake and energy expenditure.
The physiological significance of BAD/GK partnership is underscored by the findings that Bad ablation in mice phenocopies multiple parameters associated with GK loss-of-function, including abrogation of glucose-stimulated insulin secretion by b-cells, loss of hepatic glucose sensing and glucose intolerance . Initial genetic tests examining the assembly and function of the mitochondria-tethered complex containing BAD and GK provided evidence that BAD is required to nucleate the complex and to support full mitochondria-tethered GK activity. Consistent with this notion, glucose-driven mitochondrial respiration is blunted in BadÀ/À hepatocytes and primary b-cells.
Mitochondrial localization of hexokinases is thought to couple glycolysis with mitochondrial oxidative phosphorylation in that mitochondria-tethered hexokinases preferentially use the mitochondria-generated ATP to phosphorylate glucose, and the ADP produced in the process may in turn activate mitochondrial respiration (Wilson, 2003; Arden et al., 2006) . Importantly, recent studies in hepatocytes suggest that mitochondrial localization of GK may represent a functionally distinct pool of this enzyme regulated separately from the cytosolic pool, and likely exerts a dominant effect on the oxidative metabolism of glucose and lipogenesis rather than lactate production (Arden et al., 2006) . On the other hand, the mitochondrial association of GK in b-cells may significantly enhance their fuel-sensing function by ensuring an efficient rise in the ATP/ADP ratio, which constitutes the main bioenergetics currency that triggers insulin secretion in response to glucose (Wiederkehr and Wollheim, 2006) . The regulatory mechanisms in charge of maintaining the distinct subcellular pools of GK are not fully understood. Analogous to other glycolytic enzymes, the translocation of GK to distinct subcellular compartments may be facilitated through the cytoskeleton. In line with this possibility, several glycolytic enzymes, including GK, have been shown to travel on actin filaments within cells (Murata et al., 1997; Giege et al., 2003; Waingeh et al., 2006; Balasubramanian et al., 2007) . The actin cytoskeleton may help focus the glycolytic pathway toward sites of metabolic demand within the cell. Furthermore, the association of these enzymes with actin may help ensure that glycolytic intermediates traverse a shorter distance between subsequent enzymatic steps rather than diffuse in the cytoplasm. In light of these possibilities, the discovery of WAVE-1, which is an AKAP with actin remodeling properties within the mitochondria-tethered BAD/GK complex, is particularly intriguing and warrants investigation of its role in the dynamic assembly and recruitment of GK at mitochondria.
The first indication that BAD's role in glucose homeostasis is distinct from its apoptotic function came from the observation that Bad-null and Bad 3SA mice have common metabolic abnormalities, despite the fact that they represent loss-and gain-of-function models for pro-apoptotic activity of BAD, respectively . Although BAD's metabolic function is regulated by its BH3 domain, it does not co-segregate with its ability to engage anti-apoptotic BCL-2 family members . This is consistent with the observation that the metabolic changes associated with Bad ablation and transgenic overexpression of Bcl-x L in b-cells are not similar (Zhou et al., 2000b; Danial et al., 2008) . Importantly, mutational analysis suggests that phosphorylation of S155 within the BAD BH3 domain constitutes a molecular switch between its metabolic and apoptotic functions. When phosphorylated, the BAD BH3 domain engages a metabolic program marked by GK activation, glucose phosphorylation, mitochondrial respiration and ATP production ( Figure 5 ). On dephosphorylation, the BAD BH3 domain is available to bind anti-apoptotic partners, integrating death signals with the downstream apoptotic machinery at the mitochondrion. Strikingly, the BH3 domain is not only required but also sufficient to recapitulate BAD's metabolic activity. BAD BH3 helices that have been chemically reinforced through hydrocarbon stapling [(BAD SAHB compounds), (Walensky et al., 2006) ] and their phosphomimetic derivatives directly bind and activate GK to simulate BAD's effect on glucose metabolism and insulin secretion in b-cells . Interestingly, this property of the BAD BH3 domain is not universally shared with the BH3 domain of other BCL-2 family members despite significant sequence conservation. Thus, alternative ligands and functions for the BH3 domain exist. Although the BAD BH3 domain is sufficient to pharmacologically recapitulate BAD's activation of GK, the accessibility of the BH3 domain for binding and activating GK within the context of the entire BAD protein within the mitochondrial signaling complex is likely more complex. For example, while the assembly of the entire complex does not require phosphorylation of the three serine residues, activation of GK within the complex is dependent on BAD phosphorylation. In vitro reconstitution of the complex along with structural information may help shed light on both its stoichiometry and architecture.
In addition to the metabolic benefits of BAD phosphorylation and its pharmacological mimetics in endocrine tissues such as the pancreas and liver, emerging data point to a role for BAD phosphorylation status as an important determinant of b-cell survival, especially in the physiological remodeling of b-cell mass during pancreatic development and under metabolic stress similar to that associated with nutrient overload and obesity. Importantly, BAD phosphorylation is sensitive to glucose, the nutritional (fed/fasted) state, hormones and growth factors known to enhance b-cell replication and neogenesis (glucagon-like peptide-1, IGF and epidermal growth factor), suggesting that BAD's metabolic and apoptotic activities are integrated with the nutrient and hormonal regulation of b-cell function and mass (Liu et al., 2002; Danial et al., 2003 Danial et al., , 2008 Bose et al., 2005) . Neonatal b-cell apoptosis is part of a physiological program to remodel the endocrine pancreas and a quality control mechanism to select for a functional pool of b-cells with appropriate insulin secretory capacity (Freinkel et al., 1984; Pipeleers et al., 1994; Wikstrom et al., 2007) . Direct correlations between the wave of neonatal b-cell apoptosis and levels of unphosphorylated BAD have been reported (Hettiarachchi et al., 2008) . This is likely integrated with changes in survival signaling during this developmental stage where the levels of IGF-II, which is a known b-cell survival factor, decline drastically (Hogg et al., 1994; Petrik et al., 1999; Hill et al., 2000) . In adult mammals, b-cell mass is linearly proportional to body weight and tightly controlled so that insulin secretion meets insulin demand (Montanya et al., 2000) . During weight gain associated with obesity, apoptosis influences b-cell mass dynamics. Along with increased proliferation and b-cell hypertrophy, attenuated apoptosis contributes to obesity-induced b-cell mass expansion (Pick et al., 1998; Lupi et al., 2002; Sone and Kagawa, 2005) . Genetic models are just beginning to uncover the functional relevance of the intrinsic and extrinsic pathways of apoptosis in b-cell mass adaptation under these settings (Jetton et al., 2005; Liadis et al., 2007; Danial et al., 2008) . The apoptotic function of BAD limits the extent of b-cell mass expansion during nutrient overload as in high fat feeding, which further influences the sensitivity to this experimental paradigm of obesity-induced diabetes .
The exact mechanisms by which the nutrient milieu is linked to the phosphorylation status of BAD to ultimately instruct the metabolic versus apoptotic roles of this molecule remain to be determined. Within this scenario, GK may directly modulate b-cell survival beyond its ability to control the flux of glucose utilization. Indeed, b-cell mass expansion in response to high-fat diet is severely impaired in GK-null mice (Terauchi et al., 2007) . Although the contribution of elevated apoptosis as compared with decreased b-cell proliferation in the background of GK deficiency and BAD phosphorylation status was not formally assessed in these studies, the potential influence of GK on BAD's pro-apoptotic function is a provocative thesis to be experimentally tested. Importantly, the notion that, beyond catalysing glucose phosphorylation, hexokinases may carry cellular function independent of their enzymatic activity has received experimental support in lower organisms, which may hold true in mammals. For example, genetic reconstitution of a hexokinasedeficient Arabidopsis mutant with catalytically inactive hexokinase restored certain aspects of glucose signaling in this organism, including proliferation, senescence and gene expression (Moore et al., 2003) . These studies suggest that, independent of its catalysis to glucose-6-phosphate, glucose binding to hexokinase induces conformational changes required for the propagation of nutrient-sensing signals to downstream effector molecules. A pro-survival role for GK was recently reported in b-cells, using an in vitro paradigm of nutrient overload, namely chronic exposure to hyperglycemia (Federici et al., 2001; Kim et al., 2005) . GK overexpression in this context protects cells from apoptosis by binding to VDAC and preventing the association of VDAC and BAX, similar to the proposed pro-survival effect of hexokinase II (Pastorino et al., 2002; Kim et al., 2005) . However, other independent studies that used an inducible system to overexpress GK indicated a prodeath rather than a pro-survival function for GK in bcells subjected to chronic hyperglycemia . In this case, GK-mediated sensitization to death was mechanistically traced to enhanced oxidative stress. Clearly, additional studies are required to determine the role of GK in b-cell survival/death.
Although GK exerts high control strength over the flux of glucose utilization and the flow of carbons through the glycolytic pathway in hepatocytes and b-cells, low-Km hexokinases I-III are operative in other tissues. Whether BAD additionally affects the activity of these other hexokinase isoforms remains to be fully explored. Initial studies indicate that glucose utilization is blunted in mouse embryonic fibroblasts and B lymphocytes derived from BadÀ/À mice (C Pecqueur and NN Danial, unpublished observations) . Recently, another key glycolytic enzyme, phosphofructokinase-1 (PFK-1) (Figure 6 ), was identified as a BAD-binding partner in IL-3-dependent hematopoietic FL5.12 cell line (Yu et al., 2004) . Although this association does not depend on BAD's phosphorylation status, stimulation of PFK-1 depends on the phosphorylation of BAD on Thr201, a target of JNK-1 downstream of the IL-3 signaling pathway. Importantly, glycolytic rates are blunted in cells expressing a phosphorylation-defective mutant of BAD at this position (Deng et al., 2008) . Concomitant with a stimulatory effect on glycolysis, Thr201 phosphorylation inhibits BAD's apoptotic activity by interfering with its association with BCL-X L . The nature of BAD phosphoregulatory mechanisms in charge of PFK-1 activation in higher mammals is not fully clear as Thr201 present in rat and mouse BAD (GKGGSpTPSQ) is not conserved in human BAD (GRGSSAPSQ). It is possible that alternative mechanisms operate in higher organisms to mediate BAD regulation of PFK-1 activity. Interestingly, in hepatocytes and pancreatic b-cells, GK binds and activates the bi-functional enzyme 6-phosphofructose-2-kinase/fructose 2,6 bisphosphatase (PFK-2/FBP-2), which generates fructose 2,6,bisphosphate, the allosteric activator of PFK-1 ( Figure 6 ). This ultimately stimulates carbohydrate metabolism . Through its association with GK, BAD may further influence the cellular levels of fructose 2,6,bisphosphate and subsequent PFK-1 activity. Additional studies are required to Enzymatic steps associated with glycolysis and oxidative metabolism of glucose. HK, hexokinase; GK, glucokinase; PFK, phosphofructokinase; G3PDH, glyceraldehyde 3-phosphate dehydrogenase; PK, pyruvate kinase; LDH, lactate dehydrogenase; PDH, pyruvate dehydrogenase; PC, pyruvate carboxylase; SDH, succinate dehydrogenase; CPT-1, carnitine palmitoyl transferase-1; G6P, glucose 6-phosphate; F6P, fructose 6-phosphate; GAP; glyceraldehyde phosphate; F-2,6-BP, fructose 2,6-bisphosphate; NEFA, nonesterified fatty acids. examine whether PFK-2/FBP-2 and PFK-1 are components of the core BAD/GK signaling complex. Future dissection of mechanisms by which BAD impacts glycolytic flux in endocrine versus non-endocrine cells should help uncover both common and cell-type-specific aspects of BAD's metabolic role.
Summary
The BH3-only protein BAD couples survival signaling and nutrient-sensing pathways to the mitochondrial metabolism of glucose and the core apoptotic machinery. The phosphoregulatory mechanisms that converge on BAD coordinate BAD's apoptotic function with the availability of growth factors and nutrients. BAD phosphorylation not only inactivates its apoptotic function, but also actively drives a metabolic program that includes oxidative metabolism of glucose at the mitochondrion. Remarkably, BAD's dual modality in metabolism and apoptosis is controlled by its BH3 domain, which instructs BAD to adopt an apoptotic or metabolic role through selectively engaging BCL-X L or glucokinase, respectively. Alternative BH3 ligands may be one mechanism through which BCL-2 family proteins integrate apoptosis with other cellular homeostatic pathways. Participation of BAD in mitochondrial metabolism lends further support to an overarching rationale for mitochondrial localization of BCL-2 proteins and its bioenergetic consequences in cellular life and death. 
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